XM does not provide services to residents of the United States of America.
D
D

DiaSorin

News

Italy - Factors to watch on Nov. 11

CORRECTED-Italy - Factors to watch on Nov. 11 Corrects number in paragraph 6 to million from billion The following factors could affect Italian markets on Monday. Reuters has not verified the newspaper reports, and cannot vouch for their accuracy. New items are marked with (*). For a complete list of diary events in Italy please click on IT/DIA . COMPANIES ENEL ENEI.MI Brazil's solicitor general's office said on Friday that it is suing the Italian energy group for 260 million reais ($45.12 milli
A
B
E
E
G
H
L
R
S
T
U
A
B
B
D
J
M
R
R
I
U

Italy - Factors to watch on November 6

Italy - Factors to watch on November 6 The following factors could affect Italian markets on Wednesday. Reuters has not verified the newspaper reports, and cannot vouch for their accuracy. New items are marked with (*). For a complete list of diary events in Italy please click on IT/DIA . ECONOMY October services PMI HCOB data (0845 GMT). COMPANIES (*) UNICREDIT CRDI.MI The Italian bank raised its profit outlook on Wednesday and said it would start paying out half of its net income to investors
C
E
E
F
I
L
P
S
T
T
U
V
A
B
D
F
I
P
T
I
U

Diagnostics group DiaSorin's nine-month adjusted core profit up 6%

REFILE-UPDATE 1-Diagnostics group DiaSorin's nine-month adjusted core profit up 6% Adds revenue, guidance Nov 5 (Reuters) - Italian medical diagnostics group DiaSorin DIAS.MI on Tuesday posted a 6% jump in nine-month adjusted core profit to 292 million euros ($318.46 million) at constant exchange rates, driven by its immunodiagnostic segment. The group's nine-month overall revenue grew to 583 million euros compared to last year's results of 846 million euros, driven by the excellent performance
D

Diagnostics group DiaSorin's nine-month adjusted core profit up 6%

Diagnostics group DiaSorin's nine-month adjusted core profit up 6% Nov 5 (Reuters) - Italian medical diagnostics group DiaSorin DIAS.MI on Tuesday posted a 6% jump in nine-month adjusted core profit to 292 million euros ($318.46 million) at constant exchange rates, driven by its immunodiagnostic segment. ($1 = 0.9169 euros) Reporting by Michela Sta
D

Diasorin Q3 Adj. EBITDA At EUR 94 Mln

BRIEF-Diasorin Q3 Adj. EBITDA At EUR 94 Mln Nov 5 (Reuters) - DiaSorin SpA DIAS.MI : Q3 NET PROFIT EUR 45 MILLION Q3 ADJUSTED EBITDA EUR 94 MILLION Q3 REVENUE EUR 287 MILLION SEES FOR 2024 EX-COVID REVENUES ABOUT +7% COVID REVENUES ABOUT EUR 30 MILLION CONFIRMS FOR 2024 ADJUSTED EBITDA MARGIN AROUND 33% Further company coverage: DIAS.MI (Reporting
D

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.